Intranasal 5-MeO-DMT Shows Promise In Phase 2 Depression Trial
A shorter psychedelic treatment session could change how clinics approach depression care, provided meaningful benefits outlast the immediate drug experience. A randomized clinical trial…
Read MoreLatest Articles
BrainsWay Q3 Revenue Rises 34% as Deep TMS Shipments Climb 44%
November 10, 2026
Does Hyperventilation Improve ECT Seizure Quality?
November 10, 2026
Can Brain Biomarkers Personalize Depression Treatment?
November 9, 2026
COMP360 Provider Training Moves Toward Real-World Readiness
November 5, 2026
Get the Mental Health Breakthroughs
No One Else Is Talking About
Every week, we deliver the latest news, research, and real-world updates from the frontlines of interventional psychiatry.
Join the IPN Newsletter
Reach out for guest article or sponsorship opportunities
Interested in collaborating with us?
Share your details, and let’s explore how we can work together to create meaningful experiences for our audience.
